First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments

Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023

Gross proceeds made available to Calidi Biotherapeutics from transaction will total approximately $28 million, including funds held in First Light Acquisition Group’s trust account before deducting transaction expenses and debt repayments

Read more at globenewswire.com